Alcon Inc.
ALCAlcon Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (22 weeks in) while the P/E sits at the 57th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −100.0% year on year, and 193% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Alcon Inc. trades at $66.3, in a downtrend and 22 weeks into that stage. That is −10.6% against its own 200-day average. It sits at 15% of a 52-week range of $63 to $87. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 22 of stage 4. At $66.3 it trades −10.6% versus its 200-day average and sits at 15% of its 52-week range ($63–$87).
Against the market, two honest reads. Cumulative: over the last 7.4 years the stock moved +22% while the S&P 500 moved +160% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Alcon Inc. trades at 50.6× P/E, mid-range by its own standards (57th percentile). Its long-run median P/E is 44.3×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 50.6× is mid-range by its own standards (57th percentile), against a long-run median of 44.3× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −3.4% against a −14.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the −6.8%/yr price move, ~+22.1%/yr came from earnings growth and ~−28.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Alcon Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −39.3% latest against +208.8% at its 12-quarter best), ROCE holding at 3.3%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +4.9% | +6.0% | — | — |
| Profit | −3.9% | +42.3% | — | — |
| EPS | −3.4% | +42.8% | — | — |
| Stock price | −14.2% | −6.8% | −4.7% | — |
4-Factor Sector Score
25.8/100 — rank 24 of 30 in Medical Instruments & Supplies · 85% evidence confidence
Alcon Inc. scores 25.8 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 24. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 9.5 + 8.1 + 4.6 + 3.6 = 25.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Alcon Inc. reported $2.8 B of revenue in the Jun 26 quarter, +8.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 5.8% a year. The last full year, FY25, came in at $10.4 B. The last four reported quarters add to $10.9 B.
FY25 revenue came in at $10.4 B (+4.9% on the year), capping 4 years at 5.8% compound. The latest quarter (Jun 26) printed $2.8 B, +8.5% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.4% growth against the decade's 5.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.4% over the last 4 quarters against +6.1%/yr over the last 8 — stabilising; TTM profit −39.3% vs −23.1%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Alcon Inc.'s operating margin is 0.4% in the Jun 26 quarter, −9.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 7.0% to 14.2%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 0.4%, −9.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 7.0%–14.2%.
🚨 Why the margin moved: operating margin went −9.2 pp year on year while gross margin went +6.1 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Alcon Inc. earned $0.0 B of net profit in the Jun 26 quarter, −100.0% year on year. Full-year FY25 profit was $1.0 B. The 4-year compound rate is 26.7%. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.
Jun 26 profit was $0.0 B, −100.0% year on year. On the full year, FY25 printed $1.0 B (−3.9%), and the 4-year compound rate is 26.7%.
🚨 Why profit moved: revenue contributed +8.5% and the margin −9.2 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −43.7% vs revenue +8.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 193% of Alcon Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.3 B of operating cash against $1.0 B of profit. After $0.5 B of capital spending, $1.7 B was left as free cash.
FY25: operating cash of $2.3 B against reported profit of $1.0 B, leaving free cash of $1.7 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 193% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Alcon Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 6.4% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Alcon Inc. earns a ROE of 4% in FY25. That is up from a trough of 2% in FY22. Return on invested capital clears the cost of that capital by −2.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 9.4% net margin on 0.33× asset turns.
FY25 ROE is 4%, recovered from a FY22 trough of 2% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 9.4% net margin × 0.33× asset turns × 1.43× balance-sheet leverage ≈ 4.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 4.7% − 7.4% = a −2.7 pp spread. The 7.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Alcon Inc. has 3 quarters of declared dividends on file — too few for a trailing-twelve-month figure. The most recent declaration was $0.35 for Dec 25.
Alcon Inc. has declared a dividend in 3 of the last 12 reported quarters, most recently $0.35 for Dec 25. That is fewer than four quarters, so no trailing-twelve-month total is shown rather than one built from a partial year.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Alcon Inc. carries total debt of $5.3 B against shareholder equity of $21.6 B as of Jun 26, a debt-to-equity of 0.25 — effectively unlevered. On the annual view that ratio went from 0.23 in FY21 to 0.24 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $5.3 B against shareholder equity of $21.6 B — a debt-to-equity of 0.25. On the annual view, debt-to-equity went from 0.23 (FY21) to 0.24 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Alcon Inc., so this section names the gap rather than filling it. At typical trading volumes those positions would take about 8.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Alcon Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1West Pharmaceutical Services, Inc.WST | 67.1/100Favorable setup85% evidence | LEADER | 25.5/35 Revenue 12.4% · PAT 15.8% · OPM change 1.6 pp 95% evidence | 21.1/25 ROCE 21.2% · OPM 22.5% 76% evidence | 6.9/20 P/E 44.9× · PEG 2.65 65% evidence | 13.6/20 RS sector 9.5% · RS bench 16.3% · 1Y 42%7 of 12 weeks ahead 100% evidence |
| Exact sum: 25.5 + 21.1 + 6.9 + 13.6 = 67.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2LeMaitre Vascular, Inc.LMAT | 57.7/100Mixed-positive evidence81% evidence | BASING | 26.5/35 Revenue 12.8% · PAT 40% · OPM change 5.6 pp 83% evidence | 16.2/25 ROCE 3.2% · OPM 26.7% 76% evidence | 14.0/20 P/E 40.3× · PEG 1.09 65% evidence | 1.0/20 RS sector -24.3% · RS bench -19.3% · 1Y -12.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 16.2 + 14 + 1 = 57.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -24.3% and the one-year return is -12.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Merit Medical Systems, Inc.MMSI | 57.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.0/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.7/25 ROCE 2.4% · OPM 11.6% 76% evidence | 10.5/20 P/E 28.7× · PEG — 15% evidence | 13.2/20 RS sector -2.4% · RS bench 3% · 1Y 3.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 14.7 + 10.5 + 13.2 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Stevanato Group S.p.A.STVN | 57.3/100Mixed-positive evidence81% evidence | BREAKING OUT | 18.8/35 Revenue 6.9% · PAT 12.7% · OPM change 0.7 pp 83% evidence | 14.8/25 ROCE 2% · OPM 14.2% 76% evidence | 6.9/20 P/E 23.3× · PEG 2.74 65% evidence | 16.8/20 RS sector 2.6% · RS bench 8.5% · 1Y -15.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.8 + 6.9 + 16.8 = 57.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Avantor, Inc.AVTR | 57.1/100Thin evidence · provisional58% evidence | LEADER | 15.5/35 Revenue — · PAT — · OPM change -3 pp 45% evidence | 11.2/25 ROCE 1.2% · OPM 6.3% 76% evidence | 11.3/20 P/E 13.6× · PEG — 15% evidence | 19.1/20 RS sector 26.6% · RS bench 33.2% · 1Y 24.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.2 + 11.3 + 19.1 = 57.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6AtriCure, Inc.ATRC | 56.4/100Thin evidence · provisional52% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence | 9.1/25 ROCE 1.7% · OPM 0.4% 76% evidence | 9.0/20 P/E 133.2× · PEG — 15% evidence | 16.7/20 RS sector 42.7% · RS bench 50.3% · 1Y 56.8%11 of 12 weeks ahead 70% evidence |
| Exact sum: 21.6 + 9.1 + 9 + 16.7 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Intuitive Surgical, Inc.ISRG | 56.2/100Mixed-positive evidence85% evidence | BASING | 27.9/35 Revenue 20.7% · PAT 20.2% · OPM change 3.1 pp 95% evidence | 17.1/25 ROCE 5.2% · OPM 33.6% 76% evidence | 9.7/20 P/E 45.6× · PEG 2.09 65% evidence | 1.5/20 RS sector -27.8% · RS bench -23.5% · 1Y -12.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 17.1 + 9.7 + 1.5 = 56.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -27.8% and the one-year return is -12.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Repligen CorporationRGEN | 55.1/100Thin evidence · provisional58% evidence | LEADER | 19.1/35 Revenue — · PAT — · OPM change 4.3 pp 45% evidence | 10.0/25 ROCE 0.5% · OPM 8.2% 76% evidence | 8.9/20 P/E 186.9× · PEG — 15% evidence | 17.1/20 RS sector 6.7% · RS bench 12.6% · 1Y 41.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 10 + 8.9 + 17.1 = 55.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Solventum CorporationSOLV | 53.1/100Mixed-positive evidence71% evidence | LEADER | 16.6/35 Revenue -0.6% · PAT 100% · OPM change -3.3 pp 83% evidence | 11.1/25 ROCE 0.7% · OPM 4% 76% evidence | 11.4/20 P/E 8× · PEG — 15% evidence | 14.0/20 RS sector 2% · RS bench 8% · 1Y 20.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 11.1 + 11.4 + 14 = 53.1 · Decision use: Price leads the evidence: RS versus the benchmark is 8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Baxter International Inc.BAX | 52.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.8/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence | 9.8/25 ROCE 1.3% · OPM 2.4% 76% evidence | 10.3/20 P/E 39.6× · PEG — 15% evidence | 14.3/20 RS sector 1.3% · RS bench 7.1% · 1Y 2.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 9.8 + 10.3 + 14.3 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11ResMed Inc.RMD | 51.2/100Mixed-positive evidence85% evidence | BREAKING OUT | 14.2/35 Revenue 9.8% · PAT 8.8% · OPM change -3 pp 95% evidence | 17.3/25 ROCE 6.1% · OPM 30.7% 76% evidence | 11.9/20 P/E 18.7× · PEG 1.93 65% evidence | 7.8/20 RS sector -13.8% · RS bench -8.9% · 1Y -16.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 17.3 + 11.9 + 7.8 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12STAAR Surgical CompanySTAA | 49.9/100Thin evidence · provisional52% evidence | BASING | 23.7/35 Revenue — · PAT — · OPM change 76.1 pp 45% evidence | 12.0/25 ROCE 2% · OPM 8.5% 76% evidence | 9.1/20 P/E 84.6× · PEG — 15% evidence | 5.1/20 RS sector -19.2% · RS bench -13.8% · 1Y -17.7%1 of 12 weeks ahead 70% evidence |
| Exact sum: 23.7 + 12 + 9.1 + 5.1 = 49.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13AptarGroup, Inc.ATR | 45.9/100Thin evidence · provisional58% evidence | FADING | 14.9/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 15.1/25 ROCE 3.4% · OPM 10.9% 76% evidence | 10.9/20 P/E 22.6× · PEG — 15% evidence | 5.0/20 RS sector -12.9% · RS bench -7.8% · 1Y -7.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 15.1 + 10.9 + 5 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Bausch + Lomb CorporationBLCO | 45.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.7/35 Revenue — · PAT — · OPM change 10 pp 45% evidence | 8.2/25 ROCE 0.7% · OPM 2.7% 76% evidence | 8.6/20 P/E 775.5× · PEG — 15% evidence | 8.1/20 RS sector -7.8% · RS bench -2.3% · 1Y 12.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 8.2 + 8.6 + 8.1 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Align Technology, Inc.ALGN | 45.1/100Thin evidence · provisional58% evidence | ASLEEP | 17.1/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence | 15.8/25 ROCE 3.5% · OPM 13.6% 76% evidence | 10.4/20 P/E 29.3× · PEG — 15% evidence | 1.8/20 RS sector -19.2% · RS bench -14.1% · 1Y 14.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 15.8 + 10.4 + 1.8 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Envista Holdings CorporationNVST | 44.5/100Thin evidence · provisional58% evidence | FADING | 19.3/35 Revenue — · PAT — · OPM change 2.1 pp 45% evidence | 11.3/25 ROCE 1.2% · OPM 8.9% 76% evidence | 9.3/20 P/E 63× · PEG — 15% evidence | 4.6/20 RS sector -9.9% · RS bench -4.3% · 1Y 19.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 11.3 + 9.3 + 4.6 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Becton, Dickinson and CompanyBDX | 44.0/100Mixed-negative evidence85% evidence | BREAKING OUT | 12.4/35 Revenue 5.2% · PAT -1.8% · OPM change -2.3 pp 95% evidence | 13.3/25 ROCE 1.5% · OPM 13.3% 76% evidence | 8.3/20 P/E 45.6× · PEG 2.42 65% evidence | 10.0/20 RS sector -8.1% · RS bench -2.9% · 1Y -2.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 13.3 + 8.3 + 10 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Medline Inc.MDLN | 42.2/100Thin evidence · provisional55% evidence | ASLEEP | 10.9/35 Revenue 12.1% · PAT -30.6% · OPM change -4.2 pp 95% evidence | 11.6/25 ROCE 1.1% · OPM 5.1% 76% evidence | 9.7/20 P/E 49.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 12 weeks ahead 0% evidence |
| Exact sum: 10.9 + 11.6 + 9.7 + 10 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19ICU Medical, Inc.ICUI | 39.4/100Mixed-negative evidence64% evidence | LEADER | 14.3/35 Revenue -10.9% · PAT — · OPM change 0.5 pp 62% evidence | 7.5/25 ROCE 0.4% · OPM 2.6% 76% evidence | 9.2/20 P/E 69.8× · PEG — 15% evidence | 8.4/20 RS sector -3.4% · RS bench 2.2% · 1Y 18.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 7.5 + 9.2 + 8.4 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Azenta, Inc.AZTA | 37.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 8.3/35 Revenue 2% · PAT — · OPM change -101.8 pp 62% evidence | 4.4/25 ROCE -9.6% · OPM -114.5% 76% evidence | 11.5/20 P/E 2.1× · PEG — 15% evidence | 13.5/20 RS sector 2.2% · RS bench 7.5% · 1Y 6.8%8 of 12 weeks ahead 70% evidence |
| Exact sum: 8.3 + 4.4 + 11.5 + 13.5 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Warby Parker Inc.WRBY | 36.4/100Thin evidence · provisional58% evidence | ASLEEP | 15.7/35 Revenue 11.9% · PAT — · OPM change -0.4 pp 62% evidence | 6.7/25 ROCE 0.3% · OPM 0.7% 76% evidence | 8.5/20 P/E 1053.5× · PEG — 15% evidence | 5.5/20 RS sector -14.4% · RS bench -9.2% · 1Y -17.3%4 of 12 weeks ahead 70% evidence |
| Exact sum: 15.7 + 6.7 + 8.5 + 5.5 = 36.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Teleflex IncorporatedTFX | 31.4/100Adverse evidence71% evidence | ASLEEP | 6.6/35 Revenue -32.4% · PAT -138.7% · OPM change -14.6 pp 83% evidence | 8.6/25 ROCE 0.3% · OPM 3.7% 76% evidence | 10.7/20 P/E 28× · PEG — 15% evidence | 5.5/20 RS sector -8.3% · RS bench -2.7% · 1Y 4.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 6.6 + 8.6 + 10.7 + 5.5 = 31.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23DENTSPLY SIRONA Inc.XRAY | 27.8/100Adverse evidence64% evidence | ASLEEP | 8.8/35 Revenue -1% · PAT — · OPM change -11.2 pp 62% evidence | 5.5/25 ROCE -0.8% · OPM -4% 76% evidence | 11.0/20 P/E 22.6× · PEG — 15% evidence | 2.5/20 RS sector -24% · RS bench -19.5% · 1Y -22.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 8.8 + 5.5 + 11 + 2.5 = 27.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Alcon Inc.this pageALC | 25.8/100Adverse evidence85% evidence | FADING | 9.5/35 Revenue 8.3% · PAT -40.1% · OPM change -9.1 pp 95% evidence | 8.1/25 ROCE 0% · OPM 0.4% 76% evidence | 4.6/20 P/E 51.2× · PEG 6.35 65% evidence | 3.6/20 RS sector -21.3% · RS bench -16.7% · 1Y -14.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 9.5 + 8.1 + 4.6 + 3.6 = 25.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25The Cooper Companies, Inc.COO | 22.3/100Adverse evidence85% evidence | ASLEEP | 7.1/35 Revenue 6.1% · PAT -43.1% · OPM change -21.3 pp 95% evidence | 7.8/25 ROCE -0.3% · OPM -2.9% 76% evidence | 7.0/20 P/E 53.3× · PEG 2.6 65% evidence | 0.4/20 RS sector -33.5% · RS bench -29.6% · 1Y -19.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 7.1 + 7.8 + 7 + 0.4 = 22.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Pulse Biosciences, Inc.PLSE | 54.2/100Thin evidence · provisional42% evidence | LEADER | 19.2/35 Revenue — · PAT — · OPM change 98992.5 pp 19% evidence | 5.0/25 ROCE -19.4% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 85.2% · RS bench 95.7% · 1Y 181.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 5 + 10 + 20 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27BioLife Solutions, Inc.BLFS | 48.7/100Thin evidence · provisional47% evidence | LEADER | 18.0/35 Revenue — · PAT — · OPM change 2.4 pp 32% evidence | 6.0/25 ROCE 0% · OPM 0.1% 76% evidence | 8.7/20 P/E 228.4× · PEG — 15% evidence | 16.0/20 RS sector 23.8% · RS bench 30.8% · 1Y 41.2%12 of 12 weeks ahead 70% evidence |
| Exact sum: 18 + 6 + 8.7 + 16 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28MiniMed Group, Inc.MMED | 48.0/100Thin evidence · provisional44% evidence | BREAKING OUT | 23.6/35 Revenue 14.3% · PAT — · OPM change 9.3 pp 71% evidence | 4.4/25 ROCE -2.5% · OPM -11.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 23.6 + 4.4 + 10 + 10 = 48 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Alamar Biosciences, Inc.ALMR | 41.3/100Thin evidence · provisional24% evidence | BREAKING OUT | 17.8/35 Revenue — · PAT — · OPM change 17.9 pp 13% evidence | 3.5/25 ROCE -15.2% · OPM -47.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 9 weeks ahead 0% evidence |
| Exact sum: 17.8 + 3.5 + 10 + 10 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Kestra Medical Technologies, Ltd.KMTS | 37.9/100Thin evidence · provisional49% evidence | BREAKING OUT | 17.8/35 Revenue — · PAT — · OPM change -5.1 pp 45% evidence | 3.6/25 ROCE -13.9% · OPM -141.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.5/20 RS sector -10.5% · RS bench -5.4% · 1Y -3.4%9 of 12 weeks ahead 70% evidence |
| Exact sum: 17.8 + 3.6 + 10 + 6.5 = 37.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Alcon Inc.'s stock price today?
Alcon Inc. trades at $66.3, −14.2% over the past year. The company is valued at $33.0 B. The stock sits at 15% of its 52-week range of $63–$87, −10.6% versus its 200-day average. On the tape, the price is in a downtrend, 22 weeks in. — as of 17 September 2026.
What were Alcon Inc.'s latest quarterly results?
Alcon Inc. reported revenue of $2.8 B and net profit of $0.0 B for the Jun 26 quarter. Revenue rose 8.5% and profit fell 100.0% year on year. Earnings per share were $0.00. The operating margin was 0.4%, 9.2 pp lower than a year earlier. — as of 17 September 2026.
What is Alcon Inc.'s revenue?
Alcon Inc. reported revenue of $2.8 B in the Jun 26 quarter, +8.5% year on year. For the full FY25 fiscal year, revenue was $10.4 B (+4.9%). Over the last 4 years revenue compounded at 5.8% a year. — as of 17 September 2026.
What is Alcon Inc.'s profit?
Alcon Inc. earned $0.0 B of net profit in the Jun 26 quarter, −100.0% year on year. Full-year FY25 profit was $1.0 B. The operating margin ran 0.4% in the latest quarter. — as of 17 September 2026.
What is Alcon Inc.'s market cap?
Alcon Inc.'s market capitalisation is $33.0 B at a stock price of $66.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Alcon Inc.'s P/E ratio?
Alcon Inc. trades at a P/E of 50.6×, at the 57th percentile of its own 5-year range, against a long-run median of 44.3×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Alcon Inc. pay a dividend?
Yes — Alcon Inc. declared $0.35 per share for Dec 25 (3 quarters on file, too few for a trailing-twelve-month total). — as of 17 September 2026.
What is Alcon Inc.'s dividend per share?
Alcon Inc.'s most recently declared dividend is $0.35 per share for Dec 25. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
Is Alcon Inc. overvalued?
On its own history, Alcon Inc. looks mid-range: its P/E of 50.6× sits at the 57th percentile of its 5-year range (long-run median 44.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Alcon Inc. growing?
Not right now — Alcon Inc.'s latest numbers are shrinking: latest-quarter revenue +8.5% year on year, profit −100.0%, and the margin −9.2 pp at 0.4%. The 4-year compound rates are 5.8% (revenue) and 26.7% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Alcon Inc. performing?
Alcon Inc. is in a downtrend, 22 weeks in. Its latest quarter's revenue rose 8.5% and profit fell 100.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Alcon Inc. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −39.3% latest against +208.8% at its 12-quarter best), ROCE holding at 3.3%. The read comes from the last 12 quarters of growth (revenue growth +8.4% latest, profit growth −39.3% latest, eps growth −39.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Alcon Inc. in an uptrend?
No — the price is in a downtrend (week 22 of stage 4), trading −10.6% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Alcon Inc. beating the market?
On recent form, yes — Alcon Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7.4 years the stock moved +22% against the S&P 500's +160% — behind the index over the full window. — as of 17 September 2026.
Will Alcon Inc.'s stock price go up?
This page publishes no price forecast for Alcon Inc. What it measures instead: the stock price is $66.3, the price is in a downtrend 22 weeks in. Its P/E of 50.6× sits at the 57th percentile of its own 5-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Does Alcon Inc. have too much debt?
No — Alcon Inc.'s debt-to-equity is 0.25. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is Alcon Inc.'s capex?
Alcon Inc. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 17 September 2026.
What is Alcon Inc.'s cash flow?
Alcon Inc. generated $2.3 B of operating cash flow in FY25 and $1.7 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $1.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Alcon Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 193% of Alcon Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $2.3 B against reported profit of $1.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
Where is Alcon Inc. in its business cycle?
Alcon Inc.'s FY25 operating margin was 13.1%, against a 5-year band of 7.0%–14.2%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 0.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Alcon Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Alcon Inc. a stock worth studying right now?
This is not investment advice. The machine read: Alcon Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!